Zhejiang, China

Yu Dai

This inventor holds 1 USPTO granted patent. Top assignee: Hangzhou Solipharma Co., Ltd.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yu Dai. Retrieved from https://idiyas.com/inventor/yu-dai-s6ypu2ps

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Yu Dai from Zhejiang, China

Introduction

Yu Dai is an accomplished inventor based in Zhejiang, China, recognized for his significant contributions to the field of pharmaceuticals. With a focus on innovative drug formulations, he has developed novel methods that enhance the stability and efficacy of medications.

Latest Patents

Yu Dai holds a patent for the "Crystal and amorphous form of tolebrutinib, preparation method therefor, and use thereof." This patent presents a crystalline and amorphous formulation of tolebrutinib, a medication with substantial medicinal value. The crystalline form boasts several advantages including excellent stability, low moisture attraction, uniform particle size distribution, and solubility that meets medicinal requirements. This formulation promises stable storage and prevents phase transformation during development and storage, suggesting significant development potential. The amorphous variant offers improved solubility while maintaining good stability and acceptable hygroscopicity, further enhancing its medicinal applicability.

Career Highlights

Yu Dai is associated with Hangzhou Solipharma Co., Ltd., a company renowned for its innovative approaches in pharmaceutical research and development. His work has contributed to the advancement of drug formulations that prioritize stability and efficacy, showcasing his expertise in medicinal chemistry.

Collaborations

Throughout his career, Yu Dai has collaborated with various professionals, including his colleagues Xiaohong Sheng and Xiaoxia Sheng. These partnerships highlight his ability to work effectively within a team, exchanging knowledge and insights to drive innovation in pharmaceutical development.

Conclusion

Yu Dai's innovative approach to drug formulation has resulted in notable advancements in the pharmaceutical industry. His patent on tolebrutinib illustrates his commitment to enhancing medication stability and efficacy, positioning him as a valuable contributor to pharmaceutical research. As the industry continues to evolve, inventors like Yu Dai will play a pivotal role in shaping the future of medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…